药物开发商Veru于12月17日宣称,已获美国食品和药物管理局(FDA)支持,获准开展一项新试验,即将其试验性肥胖症药物enobosarm与当下流行的GLP-1药物进行联合用药试验。这一决定意味着enobosarm在肥胖症治疗领域的探索迈出重要一步,通过与GLP-1药物联合,有望发挥协同作用,为肥胖症患者提供更有效的治疗方案。Veru公司计划于明年初正式启动这项新的中期试验,以进一步评估联合用药的...
Source Link药物开发商Veru于12月17日宣称,已获美国食品和药物管理局(FDA)支持,获准开展一项新试验,即将其试验性肥胖症药物enobosarm与当下流行的GLP-1药物进行联合用药试验。这一决定意味着enobosarm在肥胖症治疗领域的探索迈出重要一步,通过与GLP-1药物联合,有望发挥协同作用,为肥胖症患者提供更有效的治疗方案。Veru公司计划于明年初正式启动这项新的中期试验,以进一步评估联合用药的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.